{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T02:54:55Z","timestamp":1794538495798,"version":"4.9.1"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Chem Biol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Histone lysine demethylase 4 (KDM4) enzymes are frequently overexpressed in cancer and are considered to be promising therapeutic targets. QC6352, which is widely used as a best-in-class KDM4 chemical probe, shows potent antitumor activity across cancer models. Using comprehensive chemical biology approaches in glioblastoma models, we demonstrate that the efficacy of QC6352 and that of its clinical analog zavondemstat are independent of KDM4 inhibition. Instead, we identify dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine biosynthesis, as the functional target driving their antiproliferative activity. Uridine supplementation and expression of an inhibitor-resistant DHODH mutant fully abrogate growth inhibition, whereas the orthogonal KDM4 inhibitor ML324, which lacks DHODH inhibition, fails to phenocopy QC6352. These findings establish QC6352 and zavondemstat as dual KDM4\u2013DHODH inhibitors and identify DHODH inhibition as the dominant driver of their antiglioblastoma efficacy, as well as demonstrating the need for orthogonal chemical probes to accurately define drug mechanisms in cells.<\/jats:p>","DOI":"10.1038\/s41589-026-02306-x","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:02:21Z","timestamp":1791277341000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["DHODH is the key target of the KDM4 inhibitor QC6352 in glioblastoma stem cells"],"prefix":"10.1038","author":[{"given":"Jayden R.","family":"Sterling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacinda R.","family":"Holtsmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George L.","family":"Joun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5470-4837","authenticated-orcid":false,"given":"Matthew S.","family":"Graus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0674-361X","authenticated-orcid":false,"given":"Tian Y.","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mani","family":"Kuchibhotla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8874-4543","authenticated-orcid":false,"given":"Terrance G.","family":"Johns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"deWeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lipin","family":"Loo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1957-9732","authenticated-orcid":false,"given":"G. Gregory","family":"Neely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4703-6658","authenticated-orcid":false,"given":"Karen","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7408-9269","authenticated-orcid":false,"given":"Chloe","family":"Shard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0494-2404","authenticated-orcid":false,"given":"Guillermo A.","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3353-1970","authenticated-orcid":false,"given":"Ashwini","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana D.","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie-Aurore","family":"Losman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1179-099X","authenticated-orcid":false,"given":"Angus J.","family":"Saxton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer R.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9614-9886","authenticated-orcid":false,"given":"Zhihe","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2322-4384","authenticated-orcid":false,"given":"Matthew T. O.","family":"Holland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul E.","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9846-6882","authenticated-orcid":false,"given":"Mathias","family":"Francois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3294-2660","authenticated-orcid":false,"given":"Andreas","family":"Kraemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2402-4157","authenticated-orcid":false,"given":"Susanne","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5507-8129","authenticated-orcid":false,"given":"Yuchen","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1659-3034","authenticated-orcid":false,"given":"Paul","family":"Workman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7625-5646","authenticated-orcid":false,"given":"Lenka","family":"Munoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"key":"2306_CR1","doi-asserted-by":"publisher","first-page":"9564","DOI":"10.1021\/acs.jmedchem.2c00680","volume":"65","author":"Q Wu","year":"2022","unstructured":"Wu, Q. et al. Recent advances with KDM4 inhibitors and potential applications. J. Med. Chem. 65, 9564\u20139579 (2022).","journal-title":"J. Med. Chem."},{"key":"2306_CR2","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1038\/s42003-024-07183-5","volume":"7","author":"J Bonnici","year":"2024","unstructured":"Bonnici, J. et al. JmjC catalysed histone H2a N-methyl arginine demethylation and C4-arginine hydroxylation reveals importance of sequence-reactivity relationships. Commun. Biol. 7, 1583 (2024).","journal-title":"Commun. Biol."},{"key":"2306_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11974","volume":"7","author":"LJ Walport","year":"2016","unstructured":"Walport, L. J. et al. Arginine demethylation is catalysed by a subset of JmjC histone lysine demethylases. Nat. Commun. 7, 11974 (2016).","journal-title":"Nat. Commun."},{"key":"2306_CR4","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abq2096","volume":"14","author":"S Singh","year":"2022","unstructured":"Singh, S. et al. Targeting KDM4 for treating PAX3-FOXO1-driven alveolar rhabdomyosarcoma. Sci. Transl. Med. 14, eabq2096 (2022).","journal-title":"Sci. Transl. Med."},{"key":"2306_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.764","volume":"12","author":"CY Lin","year":"2022","unstructured":"Lin, C. Y. et al. Inhibition of KDM4C\/c-Myc\/LDHA signalling axis suppresses prostate cancer metastasis via interference of glycolytic metabolism. Clin. Transl. Med. 12, e764 (2022).","journal-title":"Clin. Transl. Med."},{"key":"2306_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14773","volume":"8","author":"A Kawamura","year":"2017","unstructured":"Kawamura, A. et al. Highly selective inhibition of histone demethylases by de novo macrocyclic peptides. Nat. Commun. 8, 14773 (2017).","journal-title":"Nat. Commun."},{"key":"2306_CR7","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1021\/acsmedchemlett.7b00220","volume":"8","author":"YK Chen","year":"2017","unstructured":"Chen, Y. K. et al. Design of KDM4 inhibitors with antiproliferative effects in cancer models. ACS Med. Chem. Lett. 8, 869\u2013874 (2017).","journal-title":"ACS Med. Chem. Lett."},{"key":"2306_CR8","doi-asserted-by":"publisher","first-page":"5900","DOI":"10.1158\/0008-5472.CAN-17-1754","volume":"77","author":"E Metzger","year":"2017","unstructured":"Metzger, E. et al. KDM4 inhibition targets breast cancer stem\u2013like cells. Cancer Res. 77, 5900 (2017).","journal-title":"Cancer Res."},{"key":"2306_CR9","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1158\/1535-7163.MCT-23-0312","volume":"23","author":"P Pichavaram","year":"2024","unstructured":"Pichavaram, P. et al. Oncogenic cells of renal embryonic lineage sensitive to the small-molecule inhibitor QC6352 display depletion of KDM4 Levels and disruption of ribosome biogenesis. Mol. Cancer Ther. 23, 478\u2013491 (2024).","journal-title":"Mol. Cancer Ther."},{"key":"2306_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101468","volume":"5","author":"A Abu-Zaid","year":"2024","unstructured":"Abu-Zaid, A. et al. Histone lysine demethylase 4 family proteins maintain the transcriptional program and adrenergic cellular state of MYCN-amplified neuroblastoma. Cell Rep. Med. 5, 101468 (2024).","journal-title":"Cell Rep. Med."},{"key":"2306_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-023-01579-6","volume":"15","author":"K Wang","year":"2023","unstructured":"Wang, K. et al. KDM4C-mediated senescence defense is a targetable vulnerability in gastric cancer harboring TP53 mutations. Clin. Epigenetics 15, 163 (2023).","journal-title":"Clin. Epigenetics"},{"key":"2306_CR12","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1097\/CAD.0000000000001514","volume":"34","author":"C Chandhasin","year":"2023","unstructured":"Chandhasin, C. et al. TACH101, a first-in-class pan-inhibitor of KDM4 histone demethylase. Anticancer Drugs 34, 1122\u20131131 (2023).","journal-title":"Anticancer Drugs"},{"key":"2306_CR13","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41572-024-00516-y","volume":"10","author":"M Weller","year":"2024","unstructured":"Weller, M. et al. Glioma. Nat. Rev. Dis. Primers 10, 33 (2024).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"2306_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-65888-5","volume":"16","author":"GL Joun","year":"2025","unstructured":"Joun, G. L. et al. Histone methyltransferase PRDM9 promotes survival of drug-tolerant persister cells in glioblastoma. Nat. Commun. 16, 10905 (2025).","journal-title":"Nat. Commun."},{"key":"2306_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-020-01177-z","volume":"20","author":"M Li","year":"2020","unstructured":"Li, M. et al. The histone demethylase JMJD2A promotes glioma cell growth via targeting Akt-mTOR signaling. Cancer Cell Int. 20, 101 (2020).","journal-title":"Cancer Cell Int."},{"key":"2306_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-023-01608-4","volume":"15","author":"Z Wang","year":"2023","unstructured":"Wang, Z. et al. Histone demethylase KDM4B accelerates the progression of glioblastoma via the epigenetic regulation of MYC stability. Clin. Epigenetics 15, 192 (2023).","journal-title":"Clin. Epigenetics"},{"key":"2306_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-03380-2","volume":"12","author":"DH Lee","year":"2021","unstructured":"Lee, D. H. et al. Histone demethylase KDM4C controls tumorigenesis of glioblastoma by epigenetically regulating p53 and c-Myc. Cell Death Dis. 12, 89 (2021).","journal-title":"Cell Death Dis."},{"key":"2306_CR18","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1002\/ijc.32649","volume":"146","author":"J-P Mallm","year":"2020","unstructured":"Mallm, J.-P. et al. Glioblastoma initiating cells are sensitive to histone demethylase inhibition due to epigenetic deregulation. Int. J. Cancer 146, 1281\u20131292 (2020).","journal-title":"Int. J. Cancer"},{"key":"2306_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-41277-z","volume":"9","author":"BW Stringer","year":"2019","unstructured":"Stringer, B. W. et al. A reference collection of patient-derived cell line and xenograft models of proneural, classical and mesenchymal glioblastoma. Sci. Rep. 9, 4902 (2019).","journal-title":"Sci. Rep."},{"key":"2306_CR20","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.ccell.2016.09.008","volume":"30","author":"GR Villa","year":"2016","unstructured":"Villa, G. R. et al. An LXR-cholesterol axis creates a metabolic co-dependency for brain cancers. Cancer Cell 30, 683\u2013693 (2016).","journal-title":"Cancer Cell"},{"key":"2306_CR21","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/nmeth.3853","volume":"13","author":"M Hafner","year":"2016","unstructured":"Hafner, M., Niepel, M., Chung, M. & Sorger, P. K. Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs. Nat. Methods 13, 521 (2016).","journal-title":"Nat. Methods"},{"key":"2306_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38952-1","volume":"14","author":"J Sterling","year":"2023","unstructured":"Sterling, J., Baker, J. R., McCluskey, A. & Munoz, L. Systematic literature review reveals suboptimal use of chemical probes in cell-based biomedical research. Nat. Commun. 14, 3228 (2023).","journal-title":"Nat. Commun."},{"key":"2306_CR23","doi-asserted-by":"crossref","unstructured":"M\u00fcller, S., Sanfelice, D. & Workman, P. Probing cancer with small-molecule tools\u2014progress and challenges. Cancer Cell 43, 323\u2013327 (2025).","DOI":"10.1016\/j.ccell.2025.02.003"},{"key":"2306_CR24","unstructured":"Rai, G. et al. Discovery of ML324, a JMJD2 demethylase inhibitor with demonstrated antiviral activity. In Probe Reports from the NIH Molecular Libraries Program (National Center for Biotechnology Information, 2010)."},{"key":"2306_CR25","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.chembiol.2015.08.007","volume":"22","author":"L Duan","year":"2015","unstructured":"Duan, L. et al. KDM4\/JMJD2 histone demethylase inhibitors block prostate tumor growth by suppressing the expression of AR and BMYB-regulated genes. Chem. Biol. 22, 1185\u20131196 (2015).","journal-title":"Chem. Biol."},{"key":"2306_CR26","doi-asserted-by":"publisher","first-page":"3201","DOI":"10.1016\/j.bmcl.2017.05.002","volume":"27","author":"Z Fang","year":"2017","unstructured":"Fang, Z. et al. Discovery of pyrazolo[1,5-a]pyrimidine-3-carbonitrile derivatives as a new class of histone lysine demethylase 4D (KDM4D) inhibitors. Bioorg. Med. Chem. Lett. 27, 3201\u20133204 (2017).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"2306_CR27","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1038\/nprot.2014.138","volume":"9","author":"R Jafari","year":"2014","unstructured":"Jafari, R. et al. The cellular thermal shift assay for evaluating drug target interactions in cells. Nat. Protoc. 9, 2100\u20132122 (2014).","journal-title":"Nat. Protoc."},{"key":"2306_CR28","doi-asserted-by":"publisher","first-page":"117083","DOI":"10.1016\/j.trac.2023.117083","volume":"163","author":"H Wang","year":"2023","unstructured":"Wang, H., Zhu, C. & Li, D. Visualizing enzyme catalytic process using single-molecule techniques. Trends Anal. Chem. 163, 117083 (2023).","journal-title":"Trends Anal. Chem."},{"key":"2306_CR29","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1084\/jem.20190196","volume":"216","author":"SC Mack","year":"2019","unstructured":"Mack, S. C. et al. Chromatin landscapes reveal developmentally encoded transcriptional states that define human glioblastoma. J. Exp. Med. 216, 1071\u20131090 (2019).","journal-title":"J. Exp. Med."},{"key":"2306_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1191","volume":"9","author":"LM Ebert","year":"2020","unstructured":"Ebert, L. M. et al. Endothelial, pericyte and tumor cell expression in glioblastoma identifies fibroblast activation protein (FAP) as an excellent target for immunotherapy. Clin. Transl. Immunol. 9, e1191 (2020).","journal-title":"Clin. Transl. Immunol."},{"key":"2306_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17186-5","volume":"11","author":"CP Couturier","year":"2020","unstructured":"Couturier, C. P. et al. Single-cell RNA-seq reveals that glioblastoma recapitulates a normal neurodevelopmental hierarchy. Nat. Commun. 11, 3406 (2020).","journal-title":"Nat. Commun."},{"key":"2306_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-021-00906-x","volume":"13","author":"AX Chen","year":"2021","unstructured":"Chen, A. X. et al. Single-cell characterization of macrophages in glioblastoma reveals MARCO as a mesenchymal pro-tumor marker. Genome Med. 13, 88 (2021).","journal-title":"Genome Med."},{"key":"2306_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28372-y","volume":"13","author":"N Abdelfattah","year":"2022","unstructured":"Abdelfattah, N. et al. Single-cell analysis of human glioma and immune cells identifies S100A4 as an immunotherapy target. Nat. Commun. 13, 767 (2022).","journal-title":"Nat. Commun."},{"key":"2306_CR34","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.ccell.2022.02.016","volume":"40","author":"VG LeBlanc","year":"2022","unstructured":"LeBlanc, V. G. et al. Single-cell landscapes of primary glioblastomas and matched explants and cell lines show variable retention of inter- and intratumor heterogeneity. Cancer Cell 40, 379\u2013392 (2022).","journal-title":"Cancer Cell"},{"key":"2306_CR35","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.cell.2019.06.024","volume":"178","author":"C Neftel","year":"2019","unstructured":"Neftel, C. et al. An integrative model of cellular states, plasticity, and genetics for glioblastoma. Cell 178, 835\u2013849 (2019).","journal-title":"Cell"},{"key":"2306_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-021-02540-7","volume":"22","author":"JM Dempster","year":"2021","unstructured":"Dempster, J. M. et al. Chronos: a cell population dynamics model of CRISPR experiments that improves inference of gene fitness effects. Genome Biol. 22, 343 (2021).","journal-title":"Genome Biol."},{"key":"2306_CR37","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.celrep.2019.03.047","volume":"27","author":"G MacLeod","year":"2019","unstructured":"MacLeod, G. et al. Genome-wide CRISPR-Cas9 screens expose genetic vulnerabilities and mechanisms of temozolomide sensitivity in glioblastoma stem cells. Cell Rep. 27, 971\u2013986 (2019).","journal-title":"Cell Rep."},{"key":"2306_CR38","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/j.cell.2017.10.049","volume":"171","author":"A Subramanian","year":"2017","unstructured":"Subramanian, A. et al. A next generation connectivity map: L1000 platform and the first 1,000,000 profiles. Cell 171, 1437\u20131452 (2017).","journal-title":"Cell"},{"key":"2306_CR39","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.cell.2016.08.057","volume":"167","author":"DB Sykes","year":"2016","unstructured":"Sykes, D. B. et al. Inhibition of Dihydroorotate Dehydrogenase Overcomes Differentiation Blockade in Acute Myeloid Leukemia. Cell 167, 171\u2013186.e15 (2016).","journal-title":"Cell"},{"key":"2306_CR40","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1016\/j.ccell.2022.10.009","volume":"40","author":"WD Gwynne","year":"2022","unstructured":"Gwynne, W. D. et al. Cancer-selective metabolic vulnerabilities in MYC-amplified medulloblastoma. Cancer Cell 40, 1488\u20131502 (2022).","journal-title":"Cancer Cell"},{"key":"2306_CR41","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.ccell.2022.07.011","volume":"40","author":"DD Shi","year":"2022","unstructured":"Shi, D. D. et al. De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma. Cancer Cell 40, 939\u2013956 (2022).","journal-title":"Cancer Cell"},{"key":"2306_CR42","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1042\/BST20160038","volume":"44","author":"JD Young","year":"2016","unstructured":"Young, J. D. The SLC28 (CNT) and SLC29 (ENT) nucleoside transporter families: a 30-year collaborative odyssey. Biochem. Soc. Trans. 44, 869\u2013876 (2016).","journal-title":"Biochem. Soc. Trans."},{"key":"2306_CR43","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0969-2126(00)00077-0","volume":"8","author":"S Liu","year":"2000","unstructured":"Liu, S., Neidhardt, E. A., Grossman, T. H., Ocain, T. & Clardy, J. Structures of human dihydroorotate dehydrogenase in complex with antiproliferative agents. Structure 8, 25\u201333 (2000).","journal-title":"Structure"},{"key":"2306_CR44","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1038\/s41375-019-0461-5","volume":"33","author":"S Christian","year":"2019","unstructured":"Christian, S. et al. The novel dihydroorotate dehydrogenase (DHODH) inhibitor BAY 2402234 triggers differentiation and is effective in the treatment of myeloid malignancies. Leukemia 33, 2403\u20132415 (2019).","journal-title":"Leukemia"},{"key":"2306_CR45","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1021\/jm800963t","volume":"52","author":"M Davies","year":"2009","unstructured":"Davies, M. et al. Structure-based design, synthesis, and characterization of inhibitors of human and Plasmodium falciparum dihydroorotate dehydrogenases. J. Med. Chem. 52, 2683\u20132693 (2009).","journal-title":"J. Med. Chem."},{"key":"2306_CR46","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1021\/acs.jmedchem.5b01537","volume":"59","author":"SM Westaway","year":"2016","unstructured":"Westaway, S. M. et al. Cell penetrant inhibitors of the KDM4 and KDM5 families of histone lysine demethylases. 1. 3-amino-4-pyridine carboxylate derivatives. J. Med. Chem. 59, 1357\u20131369 (2016).","journal-title":"J. Med. Chem."},{"key":"2306_CR47","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1158\/2159-8290.CD-23-0536","volume":"13","author":"MM Mader","year":"2023","unstructured":"Mader, M. M. et al. Which small molecule? Selecting chemical probes for use in cancer research and target validation. Cancer Discov. 13, 2150\u20132165 (2023).","journal-title":"Cancer Discov."},{"key":"2306_CR48","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1586\/17512433.2015.1019343","volume":"8","author":"YD Fragoso","year":"2015","unstructured":"Fragoso, Y. D. & Brooks, J. B. Leflunomide and teriflunomide: altering the metabolism of pyrimidines for the treatment of autoimmune diseases. Expert Rev. Clin. Pharmacol. 8, 315\u2013320 (2015).","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"2306_CR49","first-page":"229","volume":"22","author":"S Echizenya","year":"2020","unstructured":"Echizenya, S. et al. Discovery of a new pyrimidine synthesis inhibitor eradicating glioblastoma-initiating cells. Neuro Oncol. 22, 229\u2013239 (2020).","journal-title":"Neuro Oncol."},{"key":"2306_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03441-3","volume":"9","author":"M Ladds","year":"2018","unstructured":"Ladds, M. et al. A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage. Nat. Commun. 9, 1107 (2018).","journal-title":"Nat. Commun."},{"key":"2306_CR51","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/nchembio.2050","volume":"12","author":"RM Deans","year":"2016","unstructured":"Deans, R. M. et al. Parallel shRNA and CRISPR-Cas9 screens enable antiviral drug target identification. Nat. Chem. Biol. 12, 361\u2013366 (2016).","journal-title":"Nat. Chem. Biol."},{"key":"2306_CR52","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1021\/ci200227u","volume":"51","author":"R Laskowski","year":"2011","unstructured":"Laskowski, R. & Swindells, M. LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. J. Chem. Inf. Model. 51, 2778\u20132786 (2011).","journal-title":"J. Chem. Inf. Model."},{"key":"2306_CR53","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.phrs.2018.06.023","volume":"134","author":"M Hoque","year":"2018","unstructured":"Hoque, M. et al. Changes in cell morphology guide identification of tubulin as the off-target for protein kinase inhibitors. Pharmacol. Res. 134, 166\u2013178 (2018).","journal-title":"Pharmacol. Res."},{"key":"2306_CR54","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/nmeth.1233","volume":"5","author":"A Serg\u00e9","year":"2008","unstructured":"Serg\u00e9, A., Bertaux, N., Rigneault, H. & Marguet, D. Dynamic multiple-target tracing to probe spatiotemporal cartography of cell membranes. Nat. Methods 5, 687\u2013694 (2008).","journal-title":"Nat. Methods"},{"key":"2306_CR55","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.molcel.2020.05.036","volume":"79","author":"J Lerner","year":"2020","unstructured":"Lerner, J. et al. Two-parameter mobility assessments discriminate diverse regulatory factor behaviors in chromatin. Mol. Cell 79, 677\u2013688 (2020).","journal-title":"Mol. Cell"},{"key":"2306_CR56","doi-asserted-by":"publisher","first-page":"e33125","DOI":"10.7554\/eLife.33125","volume":"7","author":"AS Hansen","year":"2018","unstructured":"Hansen, A. S. et al. Robust model-based analysis of single-particle tracking experiments with Spot-On. eLife 7, e33125 (2018).","journal-title":"eLife"},{"key":"2306_CR57","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/j.cell.2014.01.062","volume":"156","author":"J Chen","year":"2014","unstructured":"Chen, J. et al. Single-molecule dynamics of enhanceosome assembly in embryonic stem cells. Cell 156, 1274\u20131285 (2014).","journal-title":"Cell"},{"key":"2306_CR58","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).","journal-title":"Nucleic Acids Res."},{"key":"2306_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.crchbi.2022.100034","volume":"2","author":"A Kr\u00e4mer","year":"2022","unstructured":"Kr\u00e4mer, A. et al. IPP\/CNRS-A017: a chemical probe for human dihydroorotate dehydrogenase (hDHODH). Curr. Res. Chem. Biol. 2, 100034 (2022).","journal-title":"Curr. Res. Chem. Biol."},{"key":"2306_CR60","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1107\/S2059798317017235","volume":"74","author":"G Winter","year":"2018","unstructured":"Winter, G. et al. DIALS: implementation and evaluation of a new integration package Acta Crystallogr. D 74, 85\u201397 (2018).","journal-title":"Acta Crystallogr. D"},{"key":"2306_CR61","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1107\/S0907444913000061","volume":"69","author":"PR Evans","year":"2013","unstructured":"Evans, P. R. & Murshudov, G. N. How good are my data and what is the resolution? Acta Crystallogr. D 69, 1204\u20131214 (2013).","journal-title":"Acta Crystallogr. D"},{"key":"2306_CR62","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1107\/S0907444907049839","volume":"64","author":"AA Lebedev","year":"2008","unstructured":"Lebedev, A. A., Vagin, A. A. & Murshudov, G. N. Model preparation in MOLREP and examples of model improvement using X-ray data. Acta Crystallogr. D 64, 33\u201339 (2008).","journal-title":"Acta Crystallogr. D"},{"key":"2306_CR63","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1107\/S0907444904019158","volume":"60","author":"P Emsley","year":"2004","unstructured":"Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D 60, 2126\u20132132 (2004).","journal-title":"Acta Crystallogr. D"},{"key":"2306_CR64","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1107\/S0907444904023510","volume":"60","author":"AA Vagin","year":"2004","unstructured":"Vagin, A. A. et al. REFMAC5 dictionary: organization of prior chemical knowledge and guidelines for its use. Acta Crystallogr. D 60, 2184\u20132195 (2004).","journal-title":"Acta Crystallogr. D"},{"key":"2306_CR65","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1107\/S0907444911007578","volume":"67","author":"K Cowtan","year":"2011","unstructured":"Cowtan, K., Emsley, P. & Wilson, K. S. From crystal to structure with CCP4. Acta Crystallogr. D 67, 233\u2013234 (2011).","journal-title":"Acta Crystallogr. D"},{"key":"2306_CR66","doi-asserted-by":"publisher","unstructured":"Sterling, J. et al. Mechanistic deconvolution reveals DHODH as the key target of the KDM4 inhibitor QC6352. Zenodo https:\/\/doi.org\/10.5281\/zenodo.18490732 (2026).","DOI":"10.5281\/zenodo.18490732"}],"container-title":["Nature Chemical Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41589-026-02306-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41589-026-02306-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41589-026-02306-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:02:25Z","timestamp":1791277345000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41589-026-02306-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":66,"alternative-id":["2306"],"URL":"https:\/\/doi.org\/10.1038\/s41589-026-02306-x","relation":{},"ISSN":["1552-4450","1552-4469"],"issn-type":[{"value":"1552-4450","type":"print"},{"value":"1552-4469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]},"assertion":[{"value":"27 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.W. is or has been a consultant or scientific advisory board member for Alterome Therapeutics, Astex Pharmaceuticals, Black Diamond Therapeutics, Charm Therapeutics, CV6 Therapeutics, Cyclacel, EpiCombi AI, Merck KGaA, Nextech Invest, Nuevolution, Nuvectis Pharma and Vividion Therapeutics; has received grant funding from Sixth Element Capital, BACIT, Nuvectis and Vivan Therapeutics; is a Director of Derwentwater Associates, Storm Therapeutics and the nonprofit Chemical Probes Portal; holds stock and\/or options in Alterome Therapeutics, Charm Therapeutics, Chroma Therapeutics, Nextech Invest and Storm Therapeutics; and is a former employee of AstraZeneca. A.P. is the founder and CEO of Combinatics. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}